TP53 and lung cancer: Moreover, the combined administration of CU4c and CDDP enhanced cellular sensitivity by arresting the S and G2/M phases of the cell cycle and triggering apoptosis in lung cancer cells through the upregulation of p21, p53, pERK1/2, AcH3, and the Bax/Bcl-2 expression ratio.